Drug intelligence / Profile preview

saredutant

Development stage: Discontinued
Lead developer: Sanofi
Modality: Small Molecules

Overview

Saredutant is a small molecule drug that acts as a selective antagonist of the neurokinin 2 (NK2) receptor, also known as the tachykinin NK2 receptor. It was developed by Sanofi-Aventis for the treatment of major depressive disorder and generalized anxiety disorder. Saredutant demonstrated both anxiolytic and antidepressant-like effects in preclinical models, likely through modulation of central tachykinins involved in stress-related behaviors. The drug advanced to phase III clinical trials but its development was discontinued by Sanofi-Aventis in 2009[1][3][4][5][7].

Other names: saredutant succinate

Targets

TACR2 (Neurokinin-2 Receptor)

Beyond the preview

Go deeper on saredutant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on saredutant.

Explore the full profile